Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Clinical Phase 2 Study of E6011 in Japanese Subjects with Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid

Trial Profile

A Clinical Phase 2 Study of E6011 in Japanese Subjects with Primary Biliary Cholangitis Inadequately Responding to Ursodeoxycholic Acid

Discontinued
Phase of Trial: Phase II

Latest Information Update: 09 Jan 2019

At a glance

  • Drugs Quetmolimab (Primary)
  • Indications Cholangitis
  • Focus Therapeutic Use
  • Sponsors EA Pharma
  • Most Recent Events

    • 03 Jan 2019 Status changed from active, no longer recruiting to discontinued.
    • 10 Oct 2018 Planned End Date changed from 1 Feb 2022 to 1 Oct 2018.
    • 11 Sep 2018 Status changed from recruiting to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top